206 related articles for article (PubMed ID: 23714122)
1. Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.
Loi M; Di Paolo D; Soster M; Brignole C; Bartolini A; Emionite L; Sun J; Becherini P; Curnis F; Petretto A; Sani M; Gori A; Milanese M; Gambini C; Longhi R; Cilli M; Allen TM; Bussolino F; Arap W; Pasqualini R; Corti A; Ponzoni M; Marchiò S; Pastorino F
J Control Release; 2013 Sep; 170(2):233-41. PubMed ID: 23714122
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
3. Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy.
Brignole C; Bensa V; Fonseca NA; Del Zotto G; Bruno S; Cruz AF; Malaguti F; Carlini B; Morandi F; Calarco E; Perri P; Moura V; Emionite L; Cilli M; De Leonardis F; Tondo A; Amoroso L; Conte M; Garaventa A; Sementa AR; Corrias MV; Ponzoni M; Moreira JN; Pastorino F
J Exp Clin Cancer Res; 2021 Jun; 40(1):180. PubMed ID: 34078433
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.
Cossu I; Bottoni G; Loi M; Emionite L; Bartolini A; Di Paolo D; Brignole C; Piaggio F; Perri P; Sacchi A; Curnis F; Gagliani MC; Bruno S; Marini C; Gori A; Longhi R; Murgia D; Sementa AR; Cilli M; Tacchetti C; Corti A; Sambuceti G; Marchiò S; Ponzoni M; Pastorino F
Biomaterials; 2015 Nov; 68():89-99. PubMed ID: 26276694
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
6. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
8. Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer.
Shen YA; Liu CS; Chang YH; Chen PH; He CL; Wu HC; Chuang CM
Cancer Lett; 2015 Apr; 360(1):39-47. PubMed ID: 25661733
[TBL] [Abstract][Full Text] [Related]
9. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
10. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake
Bellary A; Villarreal A; Eslami R; Undseth QJ; Lec B; Defnet AM; Bagrodia N; Kandel JJ; Borden MA; Shaikh S; Chopra R; Laetsch TW; Delaney LJ; Shaw CM; Eisenbrey JR; Hernandez SL; Sirsi SR
Theranostics; 2020; 10(18):8143-8161. PubMed ID: 32724463
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
12. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
13. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors.
Chang DK; Chiu CY; Kuo SY; Lin WC; Lo A; Wang YP; Li PC; Wu HC
J Biol Chem; 2009 May; 284(19):12905-16. PubMed ID: 19276080
[TBL] [Abstract][Full Text] [Related]
15. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
16. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.
Brignole C; Marimpietri D; Gambini C; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):199-204. PubMed ID: 12880982
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma.
Viale M; Bertone V; Maric I; Cilli M; Emionite L; Bocchini V; Ponzoni M; Fontana V; De Luca F; Rocco M
Pharmacol Res; 2021 Jan; 163():105294. PubMed ID: 33217536
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
[TBL] [Abstract][Full Text] [Related]
19. Exosome mimetics derived from bone marrow mesenchymal stem cells ablate neuroblastoma tumor in vitro and in vivo.
Li M; Wang J; Guo P; Jin L; Tan X; Zhang Z; Zhanghuang C; Mi T; Liu J; Wang Z; Wu X; Wei G; He D
Biomater Adv; 2022 Nov; 142():213161. PubMed ID: 36308859
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles.
Ponzoni M; Curnis F; Brignole C; Bruno S; Guarnieri D; Sitia L; Marotta R; Sacchi A; Bauckneht M; Buschiazzo A; Rossi A; Di Paolo D; Perri P; Gori A; Sementa AR; Emionite L; Cilli M; Tamma R; Ribatti D; Pompa PP; Marini C; Sambuceti G; Corti A; Pastorino F
Small; 2018 Nov; 14(45):e1802886. PubMed ID: 30294852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
